In the current review, we describe the critical role of the PI3K/AKT/mTOR and RAF/MEK/ERK signaling pathways in carcinoma initiation and tumor development as potential strategies for tumor therapy, summarizing the recent doubts about targeting the pathway in monotherapy and combination therapy. The gene discussed is MAP2K7; the disease is neoplasm.